Trophos Successfully Completes Phase 1 Study for Novel Cardioprotective Compound, TRO40303
News Feb 25, 2011
Trophos SA a clinical stage pharmaceutical company developing innovative therapeutics from discovery to clinical validation for indications with under-served needs in neurology and cardiology, has announced the successful completion of its phase 1 dose escalation study of TRO40303, a novel mitochondria pore modulator.
TRO40303 could become the first treatment to reduce the cardiac reperfusion injury that contributes significantly to the morbidity and mortality seen after a heart attack (myocardial infarction - MI).
“We are very pleased with the highly satisfactory results of this rigorous and extensive phase 1 study of TRO40303. This will allow us to initiate our important phase 2 proof-of concept trial of TRO40303 in the second half of this year with our consortium partners in the EU funded MitoCare project,” commented Dr Jean-Louis Abitbol, Chief Medical Officer at Trophos.
Abitbol continued, “A treatment is urgently required globally to prevent cardiac reperfusion injury. This is a major problem in the care of MI patients despite the overall improvements in prognosis in recent years. There is no existing treatment for this problem that contributes to long-term morbidity, progression to heart failure and death following a MI. The role of mitochondrial permeability transition in cardiac reperfusion injury has recently been validated clinically making this is a tremendous opportunity for our novel mitochondrial pore modulator, TRO40303, discovered and developed in our laboratories to target this mechanism.”
“There are around 1.6 million cardiac reperfusion procedures performed in hospitals and specialist clinics each year in the western world alone,” added Damian Marron, Trophos’ CEO. “This program fits perfectly with Trophos strategy of creating value by targeting niche, high unmet medical need markets. Trophos is excellently positioned to deliver both on its goals with TRO40303 and with our lead product, olesoxime, in a phase 3 study for the orphan neurological disease of amyotrophic lateral sclerosis as part of the EU funded MitoTarget project.”
The objective of the phase 1 study was to assess the safety, tolerability and pharmacokinetics of single escalating doses of TRO40303 as an intravenous infusion at different rates compared with placebo in 72 healthy volunteers. The results demonstrate that TRO40303 can be safely administered by the i.v. route in humans at doses expected to be pharmacologically active. Trophos plans to present the full results of this study at a major cardiology congress in the second half of 2011.
The phase 2 proof-of-concept study of TRO40303 is to be sponsored by Trophos and performed as part of the EU funded MitoCare project (see release of December 14, 2010) by a consortium of prominent European clinical investigators, all of whom have extensive prior experience conducting and collaborating in large multi-centre clinical trials in cardiac IRI.
The principal investigator will be Professor Dan Atar from Oslo University Hospital, Norway. The study will be a placebo-controlled, phase 2 proof-of-concept study in acute MI patients with large myocardial infarct undergoing percutaneous transluminal coronary angioplasty (PTCA also known as coronary or balloon angioplasty) during percutaneous coronary intervention (PCI). TRO40303 will be administered as a single i.v. infusion prior to the reperfusion by angioplasty.
WHO welcomes the Government of Malawi’s launch of the world’s first malaria vaccine today in a landmark pilot programme. The country is the first of three in Africa in which the vaccine, known as RTS,S, will be made available to children up to 2 years of age; Ghana and Kenya will introduce the vaccine in the coming weeks.READ MORE
A research team developed a microfluidic-based drug screening chip that identifies synergistic interactions between two antibiotics in eight hours. This chip can be a cell-based drug screening platform for exploring critical pharmacological patterns of antibiotic interactions, along with potential applications in screening other cell-type agents and guidance for clinical therapies.READ MORE